Skip to main
  1. Stocks
  2. Praxis Precision Medicines
  3. Forecast
PRAX

PRAX Stock Forecast & Price Target

PRAX Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 56%
Buy 39%
Hold 0%
Sell 6%
Strong Sell 0%

Bulls say

Praxis Precision Medicine is supported by a diversified CNS pipeline with four clinical-stage assets and two proprietary platforms, giving it multiple shots on goal across movement disorders and epilepsy. Ulixacaltamide looks increasingly de-risked, with all four FDA-requested sensitivity analyses statistically significant, a long-term snapshot showing ADL gains rising from about 3 points at week 12 to roughly 6 points by week 95, and launch infrastructure already in place ahead of its 1/29/27 PDUFA. Relutrigine adds further upside with 53% placebo-adjusted seizure reduction, about 86% long-term seizure reduction at 18 months, and a broad DEE catalyst in 4Q26, while management also points to a combined $20B+ peak sales vision across the first four assets.

Bears say

Praxis Precision Medicine is viewed negatively because its valuation depends on a series of binary regulatory and clinical outcomes, including ulixacaltamide’s ongoing FDA review, possible DEA scheduling, relutrigine’s EMERALD data in 4Q26, and vormatrigine’s next steps after the POWER1 failure and restarted POWER2. The company also faces execution risk from management’s $20B+ peak sales guidance, while concerns around trial design, statistical analyses, functional unblinding, safety/tolerability, and limited differentiation versus standard of care raise the odds of weaker-than-expected uptake if approved. Financially, it is still a cash-burning biotech with significant R&D and SG&A outlays and likely needs capital markets access, so any regulatory setback or commercial delay could quickly pressure the shares.

PRAX has been analyzed by 18 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 39% recommend Buy, 0% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Praxis Precision Medicines and is not a guaranteed prediction by Public.com or investment advice.

PRAX Analyst Forecast & Price Prediction

Get the latest PRAX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRAX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Praxis Precision Medicines (PRAX) Forecast

Analysts have given PRAX a Buy based on their latest research and market trends.

According to 18 analysts, PRAX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $640.39, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $640.39, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Praxis Precision Medicines (PRAX)


PRAX Analyst Forecast & Price Prediction

Get the latest PRAX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRAX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRAX stock data and trends